Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)

NCT03281902 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03281902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03281902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)
Lead sponsor
Mayo Clinic
Phase
Observational
Overall status
Active, not recruiting
Start date
November 13, 2017
Completion date
March 4, 2028
Enrollment
68 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast carcinoma, locally advanced breast carcinoma, metastatic breast carcinoma, recurrent breast carcinoma, stage iii breast cancer ajcc v7, stage iiia breast cancer ajcc v7, stage iiib breast cancer ajcc v7, stage iiic breast cancer ajcc v7, stage iv breast cancer ajcc v6 and v7